NCT05177536View on ClinicalTrials.gov

Iberdomide Maintenance Therapy in Patients With Multiple Myeloma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 15, 2022

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2031

Conditions
Multiple Myeloma
Interventions
DRUG

Iberdomide

Iberdomide is a novel potent cereblon E3 ligase modulator

Trial Locations (2)

14263

Roswell Park Cancer Institute, Buffalo

68198

University of Nebraska Medical Center, Omaha

All Listed Sponsors
lead

University of Nebraska

OTHER